Core Viewpoint - The company reported a significant recovery in financial performance, with a notable increase in revenue and a shift from loss to profit in the latest reporting period [1] Financial Performance - The group's revenue for the six months ending September 30, 2025, increased by 8.05% to approximately RMB 807 million [1] - The group reported a profit of approximately RMB 1.883 billion, compared to a loss of approximately RMB 1.35 billion for the same period ending September 30, 2024 [1] - Earnings per share attributable to the company's owners were RMB 0.685 [1] Business Operations - The company operates the well-known "Ye Kai Tai" brand in the retail pharmacy sector within China [1] - The company is enhancing its "pharmacy + traditional Chinese medicine" store operation model, focusing on the integration of pharmaceutical retail and medical services [1] - A new traditional Chinese medicine clinic and retail pharmacy complex was opened in Wuhan [1] - The company is optimizing the operational efficiency and profitability of existing stores, leading to the closure of some underperforming locations [1] - As of September 2025, the company operates 40 retail pharmacies, 14 traditional Chinese medicine clinics, 2 dermatology clinics, and an online pharmacy [1] - The company is increasing investment in online business resources, fully developing its pharmaceutical e-commerce (B2C) and O2O instant delivery business segments [1]
北大资源(00618.HK)中期扭亏为盈至18.83亿元